Members
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | http://3sixtypublicaffairs.com/welcome/ |
| Contact: |
Bill Dempster (wdempster@3sixtypublicaffairs.com) 1 613 800.8340 |
| Description: | 3Sixty is a government relations and public policy consulting firm based in Ottawa, Canada, serving the agri-food, consumer products, health and life sciences sectors. We strive to bridge differences between how governments, stakeholders and businesses communicate and make decisions. Drawing on our business and government experience, 3Sixty provides industry-leading advice and counsel with integrity, commitment and top-notch client service. |
| Location: | Saint-Laurent, Quebec |
|---|---|
| Industry Sector: | Pharma |
| Website: | abbott.ca |
| Contact: |
Dirk van Eeden (dirk.vaneeden@abbott.com) 1 514 8327000 |
| Ownership: | Subsidiary - New York Stock Exchange (NYSE): ABT |
| Description: | Abbott Canada is an affiliate of Abbott and the first international office to be established. Today Abbott Canada employs some 2,000 individuals across the country with more than 300 based out of their headquarters in the Montreal borough of Ville Saint-Laurent. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Contact: |
Sanj Singh (sanj@adetherapeutics.com) 1 306 2615189 |
| Description: | AdeTherapeutics is a privately-held clinical-stage drug development company. Their vision is to be world wide leader in developing products that deal with complications related to surgery. AdeTherapeutics has a robust portfolio of high value products by developing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages (i.e. Phase II trials). |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.afnm.com |
| Contact: |
Owen Roberts (oroberts@afnm.com) 1 416 6456613 |
| Description: | Affinium is a specialty pharmaceutical company developing a novel class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. |
| Location: | Guelph, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.afmnet.ca |
| Contact: |
Perry Lidster (perry.lidster@afmnet.ca) 1 519 8226253 |
| Description: | Advanced Foods and Materials Network (AFMNet) is Canada's research network that focuses on foods and bio-materials and is unique globally in its breadth of researchers and infrastructure. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.aic.ca |
| Contact: |
Myles Frosst (mfrosst@aic.ca) 1 613 2329459 |
| Description: | The Agricultural Institute of Canada exists to build scientific capacity for the sustainable and profitable optimization of societal benefits that can be derived from the agro-economy. The agro-economy consists of all knowledge chains (from basic and applied research to innovation, commercialization and technology transfer) and all value chains that rely upon or focus upon agricultural output as a major input to final products. |
| Location: | Ottawa, Ontario |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.agrisoma.com |
| Contact: |
Steven F. Fabijanski (sfabijanski@agrisoma.com) 1 613 8345265 |
| Description: | Agrisoma Biosciences Inc. is a private agricultural biotechnology company using its leading edge ETL technology to create new crop varieties engineered for high-value applications such as biofuel production. |
| Location: | Saskatoon, Saskatchewan |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.agwest.sk.ca |
| Contact: |
Wilf Keller (wilf.keller@agwest.sk.ca) 1 306 975 1939 |
| Description: | Ag-West Bio Inc. is a member-based business development organization in the bioscience sector. We are a not-for-profit organization, funded by Saskatchewan’s Ministry of Agriculture and Agriculture & Agri-Food Canada's Growing Forward program. The company was created in 1989 as Ag-West Biotech and renamed Ag-West Bio in 2004. Ag-West Bio member companies include research organizations, industry (from SMEs to multinationals), research support organizations, economic development organizations and commodity groups. Members represent the biotechnology, bioproducts and biofuels, and health and nutrition sectors. Ag-West Bio is a catalyst for Saskatchewan’s bioeconomy, helping to move research to market. Entrepreneurs commercializing their innovations can come to Ag-West Bio for pathfinding and help creating a sound business plan. We collaborate with the Raj Manek Mentorship program, matching protégés with experienced mentors. Our commercialization fund has assisted many early stage companies, as well as enabling established companies expand their businesses. By hosting numerous networking events, conferences and seminars, we help our community stay connected and informed. We lead delegations to relevant conferences, such as BIO International, and help set up meetings for incoming delegations interested in doing business or finding research partners in Saskatchewan. Ag-West Bio also participates with like-minded companies from across Canada in creating awareness of the industry for the government. If you are a life science innovator or investor, contact Ag-West Bio. www.agwest.sk.ca |
| Location: | Toronto, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.aimtherapeutics.com |
| Contact: |
Frank Gleeson (fgleeson@aimtherapeutics.com) 1 647 237 3691 |
| Description: | AIM is a drug development company focused on respiratory diseases. They are developing a novel class of patented non-steroidal, immune modulating drug candidates which exhibit potent anti-inflammatory effects and a favourable safety profile in numerous animal models of disease. Their first clinical candidate will complete a Phase 1 trial in Q2/11. The intended lead indication is moderate to severe asthma. AIM's business model is to enter into licensing or co-development arrangements to progress AIM-102 into pivotal Phase 2 development while they advance other molecules in their pipeline to IND. |
| Location: | MONTREAL, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.alethiabio.com |
| Contact: |
Yves Cornellier (info@alethiabio.com) 1 514 858 7666 |
| Description: | Alethia Biotherapeutics is engaged in the discovery and development of targeted therapeutics. The Company has prioritized the development of monoclonal antibodies with improved disease specificity against targets derived from its target discovery platform. |
| Location: | Cheshire, Connecticut |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.alxn.com |
| Contact: |
Irving Adler (clinicaltrials@alxn.com) 1 203 2722596 |
| Ownership: | Public - NASDAQ: ALXN |
| Description: | Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, neurologic disorders, ophthalmic, transplant, other inflammatory disorders, and cancer. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.allontherapeutics.com |
| Contact: |
Gordon C. McCauley (gmccauley@allontherapeutics.com) 1 604 7360634 |
| Ownership: | Public - Toronto Stock Exchange (TSX): NPC |
| Description: | Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon’s lead drug davunetide, is proceeding in a Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA. This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.amgen.ca |
| Contact: |
Natasha Bond (natashab@amgen.com) 1 905 2853000 |
| Ownership: | Subsidiary - NASDAQ: AMGN |
| Description: | Amgen Canada applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government, and patient organizations. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.amorfix.com/ |
| Contact: |
James Parsons (james.parsons@amorfix.com) 1 416 8476898 |
| Ownership: | Public - Toronto Stock Exchange (TSX): AMF |
| Description: | Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company creating therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's disease (AD), cancer and ALS. Amorfix utilizes it computational discovery platform, ProMIS, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection technology enables the specific identification and mearurement of very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a predictive screening test for AD. |
| Location: | Montreal, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.angiochem.com |
| Contact: |
Catherine Gagnon (cgagnon@angiochem.com) 1 514 7887800 |
| Description: | Angiochem is a clinical-stage biotechnology company developing a new class of breakthrough drugs to treat brain diseases and brain-related disorders. Moving beyond the barrier of proof and currently in clinical and preclinical studies, these novel pharmaceuticals are composed of small molecules and biologics designed to treat brain cancer, Parkinson’s, type 2 diabetes, obesity, pain, and other unmet medical needs. |
| Location: | Vancouver, British Columbia |
|---|---|
| Industry Sector: | Medical Technology |
| Website: | www.angiotech.com |
| Contact: |
K. Thomas Bailey (ir@angio.com) 1 604 221 7676 |
| Ownership: | Public - Tokyo Stock Exchange (TSE): ANPIQ.PK |
| Description: | Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. |
| Location: | St. John's, Newfoundland |
|---|---|
| Industry Sector: | Biotechnology - other |
| Website: | www.aquabounty.com |
| Contact: |
David A. Frank (investors@aquabounty.com) 1 709 738-4638 |
| Ownership: | Subsidiary - : |
| Description: | Aqua Bounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture. |
| Location: | Richmond, British Columbia |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.aqxpharma.com |
| Contact: |
Kamran Alam (info@aqxpharma.com) 1 604 629 9223 |
| Description: | Aquinox Pharmaceuticals is a private, venture-backed biopharmaceutical company committed to the discovery, development and commercialization of novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer. |
| Location: | San Fransisco, California |
|---|---|
| Industry Sector: | Professional Services and Consulting |
| Website: | www.arnoldporter.com |
| Contact: |
Todd Lorenz (Todd.lorenz@aporter.com) 1 415 356.3000 |
| Description: | Arnold & Porter LLP's San Francisco office provides the firm's clients with sophisticated advice and representation, with particular emphasis on complex commercial litigation, securing and enforcing intellectual property rights, environmental compliance and litigation, and antitrust litigation. |
| Location: | Quebec, Quebec |
|---|---|
| Industry Sector: | Biotechnology - Therapeutics and Diagnostics |
| Website: | www.asmacure.com |
| Contact: |
Martin Driscoll (martin.driscoll@asmacure.com) 1 418 780 4255 |
| Description: | Asmacure Ltée is focused on the development of nicotinic receptor modulators for the treatment of inflammatory diseases. |
| Location: | Markham, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.astellas.ca/ |
| Contact: |
Michelle Reale (michelle.reale@ca.astellas.com) 1 905 4707990 |
| Ownership: | Subsidiary - : |
| Description: | Astellas Pharma Canada, Inc., is recognized as the first Japanese pharmaceutical company in Canada. They are involved in clinical research and development as well as the sales and marketing of products in their key therapeutic areas of immunology, infectious disease, cardiology, urology and dermatology. The drugs that they develop and market are used to treat heart disease, transplant patients, and those with infections or serious skin diseases such as eczema and psoriasis. |
| Location: | Mississauga, Ontario |
|---|---|
| Industry Sector: | Pharma |
| Website: | www.astrazeneca.ca |
| Contact: |
Nicklas Westerholm (IR@astrazeneca.com) 1 905 277 7111 |
| Ownership: | Subsidiary - : |
| Description: | AstraZeneca Canada is an operating subsidiary of a global research based pharmaceutical company. Currently they are most interested in talking with companies that have products that are in pre-registration, registered and/or currently marketed. |
| Location: | Edmonton, Alberta |
|---|---|
| Industry Sector: | Biotechnology / R&D Services |
| Website: | www.atgcell.com |
| Contact: |
(info@atgcell.com) 1 780 450 5519 |
| Description: | ATGCell Inc specializes in the development, production and marketing of recombinant proteins and stably expressing mammalian cell lines for life science researchers and pharmaceutical companies, using state-of-the-art expression and purification platform, and stable cell line generation system. |
| Location: | North Vancouver, British Columbia |
|---|---|
| Industry Sector: | Medical Technology |
| Website: | www.augurex.com |
| Contact: |
Norma K. Biln 1 778 839 3319 |
| Description: | Augurex Life Sciences Corp. develops biomarkers, which are substances that indicate what is going on in the body, thereby making them useful for diagnosing and managing patients’ diseases through the use of simple blood tests. |
| Location: | Malvern, Victoria |
|---|---|
| Industry Sector: | Public / Non-Profit Organizations |
| Website: | www.ausbiotech.org |
| Contact: |
Anna Lavelle (admin@ausbiotech.org) 61 3 98281404 |
| Description: | AusBiotech is dedicated to the development, growth and prosperity of the Australian biotechnology industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world. |
